Stereotactic body radiation therapy (SBRT) for genitourinary malignancies.

Bin S. Teh, Hiromichi Ishiyama, Thomas Mathews, B. Xu, E. Brian Butler, Nina A. Mayr, Simon S. Lo, Jiade J. Lu, Angel I. Blanco, Arnold C. Paulino, Robert D. Timmerman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Stereotactic body radiation therapy (SBRT) is a novel treatment modality in radiation oncology that delivers a very high dose of radiation to the tumor target with high precision using single or a small number of fractions. SBRT is the result of technological advances in patient/tumor immobilization, image guidance, and treatment planning and delivery. This modality is safe and effective in both early stage primary cancer and oligometastases. Compared to the use of stereotactic radiosurgery for other tumor sites, SBRT is slow to be adopted in the management of genitourinary malignancies. There are now emerging data that show the safety and efficacy of this treatment modality in genitourinary (GU) malignancies especially in prostate cancer and renal cell carcinoma. Preclinical data, clinical experience, and challenges are reviewed and discussed.

Original languageEnglish (US)
Pages (from-to)255-262
Number of pages8
JournalDiscovery medicine
Volume10
Issue number52
StatePublished - Sep 2010

Fingerprint

Radiotherapy
Neoplasms
Radiation Oncology
Radiosurgery
Renal Cell Carcinoma
Immobilization
Prostatic Neoplasms
Radiation
Safety
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Teh, B. S., Ishiyama, H., Mathews, T., Xu, B., Butler, E. B., Mayr, N. A., ... Timmerman, R. D. (2010). Stereotactic body radiation therapy (SBRT) for genitourinary malignancies. Discovery medicine, 10(52), 255-262.

Stereotactic body radiation therapy (SBRT) for genitourinary malignancies. / Teh, Bin S.; Ishiyama, Hiromichi; Mathews, Thomas; Xu, B.; Butler, E. Brian; Mayr, Nina A.; Lo, Simon S.; Lu, Jiade J.; Blanco, Angel I.; Paulino, Arnold C.; Timmerman, Robert D.

In: Discovery medicine, Vol. 10, No. 52, 09.2010, p. 255-262.

Research output: Contribution to journalArticle

Teh, BS, Ishiyama, H, Mathews, T, Xu, B, Butler, EB, Mayr, NA, Lo, SS, Lu, JJ, Blanco, AI, Paulino, AC & Timmerman, RD 2010, 'Stereotactic body radiation therapy (SBRT) for genitourinary malignancies.', Discovery medicine, vol. 10, no. 52, pp. 255-262.
Teh BS, Ishiyama H, Mathews T, Xu B, Butler EB, Mayr NA et al. Stereotactic body radiation therapy (SBRT) for genitourinary malignancies. Discovery medicine. 2010 Sep;10(52):255-262.
Teh, Bin S. ; Ishiyama, Hiromichi ; Mathews, Thomas ; Xu, B. ; Butler, E. Brian ; Mayr, Nina A. ; Lo, Simon S. ; Lu, Jiade J. ; Blanco, Angel I. ; Paulino, Arnold C. ; Timmerman, Robert D. / Stereotactic body radiation therapy (SBRT) for genitourinary malignancies. In: Discovery medicine. 2010 ; Vol. 10, No. 52. pp. 255-262.
@article{cae0e0f7d7024a748aec5afa708e1fb1,
title = "Stereotactic body radiation therapy (SBRT) for genitourinary malignancies.",
abstract = "Stereotactic body radiation therapy (SBRT) is a novel treatment modality in radiation oncology that delivers a very high dose of radiation to the tumor target with high precision using single or a small number of fractions. SBRT is the result of technological advances in patient/tumor immobilization, image guidance, and treatment planning and delivery. This modality is safe and effective in both early stage primary cancer and oligometastases. Compared to the use of stereotactic radiosurgery for other tumor sites, SBRT is slow to be adopted in the management of genitourinary malignancies. There are now emerging data that show the safety and efficacy of this treatment modality in genitourinary (GU) malignancies especially in prostate cancer and renal cell carcinoma. Preclinical data, clinical experience, and challenges are reviewed and discussed.",
author = "Teh, {Bin S.} and Hiromichi Ishiyama and Thomas Mathews and B. Xu and Butler, {E. Brian} and Mayr, {Nina A.} and Lo, {Simon S.} and Lu, {Jiade J.} and Blanco, {Angel I.} and Paulino, {Arnold C.} and Timmerman, {Robert D.}",
year = "2010",
month = "9",
language = "English (US)",
volume = "10",
pages = "255--262",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "52",

}

TY - JOUR

T1 - Stereotactic body radiation therapy (SBRT) for genitourinary malignancies.

AU - Teh, Bin S.

AU - Ishiyama, Hiromichi

AU - Mathews, Thomas

AU - Xu, B.

AU - Butler, E. Brian

AU - Mayr, Nina A.

AU - Lo, Simon S.

AU - Lu, Jiade J.

AU - Blanco, Angel I.

AU - Paulino, Arnold C.

AU - Timmerman, Robert D.

PY - 2010/9

Y1 - 2010/9

N2 - Stereotactic body radiation therapy (SBRT) is a novel treatment modality in radiation oncology that delivers a very high dose of radiation to the tumor target with high precision using single or a small number of fractions. SBRT is the result of technological advances in patient/tumor immobilization, image guidance, and treatment planning and delivery. This modality is safe and effective in both early stage primary cancer and oligometastases. Compared to the use of stereotactic radiosurgery for other tumor sites, SBRT is slow to be adopted in the management of genitourinary malignancies. There are now emerging data that show the safety and efficacy of this treatment modality in genitourinary (GU) malignancies especially in prostate cancer and renal cell carcinoma. Preclinical data, clinical experience, and challenges are reviewed and discussed.

AB - Stereotactic body radiation therapy (SBRT) is a novel treatment modality in radiation oncology that delivers a very high dose of radiation to the tumor target with high precision using single or a small number of fractions. SBRT is the result of technological advances in patient/tumor immobilization, image guidance, and treatment planning and delivery. This modality is safe and effective in both early stage primary cancer and oligometastases. Compared to the use of stereotactic radiosurgery for other tumor sites, SBRT is slow to be adopted in the management of genitourinary malignancies. There are now emerging data that show the safety and efficacy of this treatment modality in genitourinary (GU) malignancies especially in prostate cancer and renal cell carcinoma. Preclinical data, clinical experience, and challenges are reviewed and discussed.

UR - http://www.scopus.com/inward/record.url?scp=79952199462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952199462&partnerID=8YFLogxK

M3 - Article

C2 - 20875347

AN - SCOPUS:79952199462

VL - 10

SP - 255

EP - 262

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 52

ER -